Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwAL 2022 | ALL over the years

Dieter Hoelzer and Sabina Chiaretti • 29 Sep 2022
iwAL 2022
Acute Lymphoblastic Leukemia Leukemia

Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, and Dieter Hoelzer, MD, PhD, Onkologikum Frankfurt am Museumsufer, Frankfurt, Germany, discuss advances in the acute lymphoblastic leukemia (ALL) treatment landscape over the years. This discussion took place at the 4th International Workshop on Acute Leukemias (iwAL), which was held in Nice, France, on 16 – 18 September 2022.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Dieter Hoelzer

The evolving landscape of ALL therapy and the impact of MRD 15:02
The evolving landscape of ALL therapy and the impact of MRD
Dieter Hoelzer et al. • 17 May 2019
MRD negativity in ALL 1:57
MRD negativity in ALL
Dieter Hoelzer • 26 Mar 2019
CAR T-cells and BiTEs for hematological malignancies 1:59
CAR T-cells and BiTEs for hematological malignancies
Dieter Hoelzer • 26 Mar 2019
New aims and next steps for adult ALL induction therapy 1:45
New aims and next steps for adult ALL induction therapy
Dieter Hoelzer • 22 Jun 2017

More from Sabina Chiaretti

New frontiers in ALL – MRD for clinical practice
Robin Foà et al. • 29 Sep 2022
T-cell engagers and treating relapsed ALL
Bijal Shah et al. • 29 Sep 2022
MRD monitoring for Ph+ ALL in the GIMEMA ALL2820 trial 1:28
MRD monitoring for Ph+ ALL in the GIMEMA ALL2820 trial
Sabina Chiaretti • 7 Dec 2024
Important considerations when treating patients with Ph+ ALL: MRD monitoring, CNS relapse & more 1:49
Important considerations when treating patients with Ph+ ALL: MRD monitoring, CNS relapse & more
Sabina Chiaretti • 7 Dec 2024

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals